Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7265757 | 0.80 | LTA4H (0.50) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL22129853 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL11576945 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL435149 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL9212518 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL122719 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL3893562 | 0.79 | LTA4H (0.92) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL28454211 | 0.76 | LTA4H (0.57) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL28589935 | 0.76 | LTA4H (0.57) | LTA4HTSHRMAOANR1H2BAX | |
| SCHEMBL5450 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-113620869-B | Preparation method of betrixaban | 江西同和药业股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-113620869-A | Preparation method of betrixaban | 江西同和药业股份有限公司 | 2021-11-09 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| CN-118791384-A | Synthesis process of famoxadone intermediate 2- (4-phenoxyphenyl) ethyl lactate | 安徽广信农化股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-116730939-A | Preparation method of famoxadone characteristic impurities | 如东众意化工有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-113620869-B | Preparation method of betrixaban | 江西同和药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023057548-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | WO | disclosed |
| CN-113024565-B | Radioactive isotope carbon-14 labeled ibrutinib and synthesis method thereof | 上海启甄环境科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
| US-4136200-A | PHENYLBUTANOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-01-23 | — | — | US | disclosed |
| US-4049823-A | Phenylbutanol derivatives and compositions containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3980795-A | Pyrazolidinones and a process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-09-14 | — | — | US | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | LTA4H 2624/4885TSHR 1000/4885MAOA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.